This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Batra, S. Articles by Maurer, B. J. Search for Related Content PubMed PubMed Citation Articles by Batra, S. Articles by Maurer, B. J.

Fenretinide Cytotoxicity for Ewing’s Sarcoma and Primitive Neuroectodermal Tumor Cell Lines Is Decreased by Hypoxia and Synergistically Enhanced by Ceramide Modulators

¹ Division of Hematology-Oncology, Children’s Hospital Los Angeles; ² University of Southern California-Children’s Hospital Los Angeles Institute for Pediatric Clinical Research; and Departments of ³ Pediatrics, ⁴ Pathology, and ⁵ Cell and Neurobiology, University of Southern California, Keck School of Medicine, Los Angeles, California

Patients with disseminated Ewing’s family of tumors (ESFT) often experience drug-resistant relapse. We hypothesize that targeting minimal residual disease with the cytotoxic retinoid N-(4-hydroxyphenyl) retinamide (4-HPR; fenretinide) may decrease relapse. We determined the following: (a) 4-HPR cytotoxicity against 12 ESFT cell lines in vitro; (b) whether 4-HPR increased ceramide species (saturated and desaturated ceramides); (c) whether physiological hypoxia (2% O₂) affected cytotoxicity, mitochondrial membrane potential (_m) change, or ceramide species or reactive oxygen species levels; (d) whether cytotoxicity was enhanced by L-threo-dihydrosphingosine (safingol); (e) whether physiological hypoxia increased acid ceramidase (AC) expression; and (f) the effect of the AC inhibitor N-oleoyl-ethanolamine (NOE) on cytotoxicity and ceramide species. Ceramide species were quantified by thin-layer chromatography and scintillography. Cytotoxicity was measured by a fluorescence-based assay using digital imaging microscopy (DIMSCAN). Gene expression profiling was performed by oligonucleotide array analysis. We observed, in 12 cell lines tested in normoxia (20% O₂), that the mean 4-HPR LC₉₉ (the drug concentration lethal to 99% of cells) = 6.1 ± 5.4 µM (range, 1.7–21.8 µM); safingol (1–3 µM) synergistically increased 4-HPR cytotoxicity and reduced the mean 4-HPR LC₉₉ to 3.2 ± 1.7 µM (range, 2.0–8.0 µM; combination index < 1). 4-HPR increased ceramide species in the three cell lines tested (up to 9-fold; P < 0.05). Hypoxia (2% O₂) reduced ceramide species increase, _m loss, reactive oxygen species increase (P < 0.05), and 4-HPR cytotoxicity (P = 0.05; 4-HPR LC₉₉, 19.7 ± 23.9 µM; range, 2.3–91.4). However, hypoxia affected 4-HPR + safingol cytotoxicity to a lesser extent (P = 0.04; 4-HPR LC₉₉, 4.9 ± 2.3 µM; range, 2.0–8.2). Hypoxia increased AC RNA expression; the AC inhibitor NOE enhanced 4-HPR-induced ceramide species increase and cytotoxicity. The antioxidant N-acetyl-L-cysteine somewhat reduced 4-HPR cytotoxicity but did not affect ceramide species increase. We conclude the following: (a) 4-HPR was active against ESFT cell lines in vitro at concentrations achievable clinically, but activity was decreased in hypoxia; and (b) combining 4-HPR with ceramide modulators synergized 4-HPR cytotoxicity in normoxia and hypoxia.

This article has been cited by other articles:

				B. J. Maurer, O. Kalous, D. W. Yesair, X. Wu, J. Janeba, V. Maldonado, V. Khankaldyyan, T. Frgala, B.-C. Sun, R. T. McKee, et al. Improved Oral Delivery of N-(4-Hydroxyphenyl)Retinamide with a Novel LYM-X-SORB Organized Lipid Complex Clin. Cancer Res., May 15, 2007; 13(10): 3079 - 3086. [Abstract] [Full Text] [PDF]

				J. G. Villablanca, M. D. Krailo, M. M. Ames, J. M. Reid, G. H. Reaman, and C. P. Reynolds Phase I Trial of Oral Fenretinide in Children With High-Risk Solid Tumors: A Report From the Children's Oncology Group (CCG 09709) J. Clin. Oncol., July 20, 2006; 24(21): 3423 - 3430. [Abstract] [Full Text] [PDF]

				M. G. Villani, V. Appierto, E. Cavadini, A. Bettiga, A. Prinetti, M. Clagett-Dame, R. W. Curley, and F. Formelli 4-Oxo-Fenretinide, a Recently Identified Fenretinide Metabolite, Induces Marked G2-M Cell Cycle Arrest and Apoptosis in Fenretinide-Sensitive and Fenretinide-Resistant Cell Lines. Cancer Res., March 15, 2006; 66(6): 3238 - 3247. [Abstract] [Full Text] [PDF]

				A. Schulz, T. Mousallem, M. Venkataramani, D.-A. Persaud-Sawin, A. Zucker, C. Luberto, A. Bielawska, J. Bielawski, J. C. M. Holthuis, S. M. Jazwinski, et al. The CLN9 Protein, a Regulator of Dihydroceramide Synthase J. Biol. Chem., February 3, 2006; 281(5): 2784 - 2794. [Abstract] [Full Text] [PDF]

				S. S. Myatt, C. P.F. Redfern, and S. A. Burchill p38MAPK-Dependent Sensitivity of Ewing's Sarcoma Family of Tumors to Fenretinide-Induced Cell Death Clin. Cancer Res., April 15, 2005; 11(8): 3136 - 3148. [Abstract] [Full Text] [PDF]

				A. Argon, M. Basaran, F. Yaman, Y. Dizdar, B. Sakar, H. Camlica, S. E. Bavbek, H. Ozger, E. Darendeliler, and H. Onat Ewing's Sarcoma of the Axial System in Patients Older Than 15 Years: Dismal Prognosis Despite Intensive Multiagent Chemotherapy and Aggressive Local Treatment Jpn. J. Clin. Oncol., November 1, 2004; 34(11): 667 - 672. [Abstract] [Full Text] [PDF]